Loading the section
The price of Halozyme Therapeutics, Inc. (HALO) on October 9, 2026 is 111.69 USD, +1.69% on the day. Over 52 weeks the stock traded between 61.23 USD and 116.85 USD; the price now sits 87% of the way up that range. Over the past year the price changed by +66.37%. The P/E ratio is 37.3, which is above the sector median (24.8). Market capitalization is 13.02 billion USD, rank 8 among 128 stocks of the same industry with a known capitalization.
Prices delayed by 15 minutes
Next earnings report: 02 November 2026 · Earnings calendar
Halozyme Therapeutics, Inc. trades on Nasdaq under the ticker HALO. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks HALO has traded between 61.23 $ and 116.85 $. As of 09 October 2026 the price stood 87.40 % of the way from the 52-week low to the high.
Over one year HALO shares rose 66.37 %; over six months they rose 63.74 %. Volatility over 90 days is 41.53 %. Dividends are not included: this is price change only, as of 09 October 2026.
HALO trades at a price-to-earnings ratio of 37.3, above the sector median of 24.8. Price to sales is 8.6, above the sector median of 3.9. Price to book is 59.3, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 109.41 | 110.64 | 107.41 | 109.84 | 2M |
| 07 October 2026 | 111.62 | 114.00 | 110.16 | 110.79 | 2M |
| 06 October 2026 | 108.87 | 111.25 | 107.43 | 109.72 | 2M |
| 05 October 2026 | 109.62 | 109.87 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Halozyme owns an enzyme that lets a drug be injected under the skin instead of infused, and takes royalties for it.
Large biologic drugs have to be infused intravenously over hours in a clinic. The company's enzyme temporarily loosens subcutaneous tissue, and the same drug is given as an injection in minutes. For the patient that is the difference between a hospital trip and an injection at home; for the manufacturer it is a way to extend a brand's life.
The company sells nothing itself: it licenses the technology to pharmaceutical giants and takes a share of their sales. Costs are minimal, so profitability is exceptionally high. Risks: expiry of the patents on the technology itself, dependence on a few partner drugs and litigation. The company pays no dividend but buys back stock actively.
Address:12390 EL CAMINO REAL, SAN DIEGO, CA, 92130, US
Halozyme Therapeutics, Inc. reported revenue of 1.5B $ and net income of 349M $ over the last four quarters. Net margin is 23.13 %. Revenue changed by +39.12 % year over year. Earnings per share are 2.85 $. Market capitalisation is 13.0B $.
HALO has a return on equity of 158.83 %, above the sector median of −41.68 %. Return on assets is 13.05 %, above the sector median of −32.11 %. Operating margin is 33.94 %, above the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| KODKodiak Sciences Inc | 99.25 | +5.29 % | 214M |
| 107.68 |
| 108.31 |
| 2M |
| 02 October 2026 | 106.96 | 109.99 | 106.65 | 109.86 | 3M |
| 01 October 2026 | 109.93 | 110.50 | 106.84 | 106.94 | 2M |
| 30 September 2026 | 111.54 | 112.45 | 110.35 | 110.40 | 4M |
| 29 September 2026 | 112.89 | 114.52 | 111.03 | 111.56 | 3M |
| 28 September 2026 | 113.34 | 113.94 | 112.10 | 112.89 | 2M |
| 25 September 2026 | 115.36 | 115.63 | 113.43 | 113.90 | 2M |
| 24 September 2026 | 112.13 | 116.09 | 111.07 | 115.22 | 3M |
| 23 September 2026 | 116.85 | 116.85 | 112.18 | 112.44 | 3M |
| 22 September 2026 | 111.50 | 115.18 | 110.95 | 115.13 | 4M |
| 21 September 2026 | 112.80 | 113.47 | 111.05 | 111.45 | 3M |
| 18 September 2026 | 109.72 | 112.66 | 109.38 | 112.45 | 10M |
| 17 September 2026 | 107.08 | 110.88 | 106.82 | 109.68 | 2M |
| 16 September 2026 | 106.66 | 109.63 | 105.50 | 108.44 | 2M |
| 15 September 2026 | 108.14 | 108.14 | 106.14 | 106.25 | 1M |
| 14 September 2026 | 108.00 | 108.61 | 106.65 | 107.94 | 912,500 |
| 11 September 2026 | 107.96 | 108.23 | 106.34 | 107.20 | 861,500 |